List view / Grid view
4 June 2011 | By Johnson & Johnson
This study represents the first randomized, double-blind, placebo controlled Phase III trial to evaluate CTCs as a potential biomarker for overall survival...
28 April 2011 | By Johnson & Johnson
Johnson & Johnson and Synthes announce definitive merger agreement to create world’s most comprehensive orthopaedics business...
15 April 2011 | By Merck
Merck and Johnson & Johnson and its subsidiary Centocor Ortho Biotech Inc., announced that the companies have reached an agreement...
8 April 2011 | By Johnson & Johnson
Johnson & Johnson announced today it will pay $70,006,316 in fines...
22 March 2011 | By Limewash Media & Design Ltd
Isogenica Ltd today announced that it has executed a services agreement with J&JPRD...
8 February 2011 | By Johnson & Johnson
Johnson & Johnson and Crucell N.V. provide further information regarding Johnson & Johnson's proposed acquisition of Crucell...
1 December 2010 | By Johnson & Johnson
Janssen announced a research agreement to collaborate with GE Healthcare...
9 November 2010 | By NG Online News
Senior executives from Eli Lilly, AstraZeneca, Johnson and Johnson & Pfizer to discuss the ROI for "non-surrogate" biomarkers, dose selection biomarkers and biomarkers of efficacy.
1 November 2010 | By Mario Hellings, Tom Van den Kerkhof, Jeroen Geens and Steve Mehrman, Johnson & Johnson
As cited by the FDA, “Process Analytical Technology (PAT) is a system for designing, analysing, and controlling manufacturing through timely measurements (i.e., during processing) of critical quality and performance attributes of raw and in-process materials and processes with the goal of ensuring final product quality.”1 The main goal of PAT…
18 October 2010 | By Emma Naylor, NG Online News
Pharmaceutical heads met last week as a result of a drugs recall after an ingrediant mix up in breast cancer pill Anastrozole.
28 June 2010 | By Johnson & Johnson
OMJPI today announced...
29 May 2009 | By
As the time-to-market of pharmaceutical products has elongated, while its prices are under big pressure, cost saving is currently essential in the pharmaceutical industry.
7 February 2009 | By
The current cost of developing a new medicine for the treatment of human disease has been estimated at $1 to $2 billion (€750-1.5 million1,2). Given progressive increases in the cost of developing new drugs, pharmaceutical companies are facing significant pressure to streamline discovery methods and increase the translational efficiency of…
19 June 2008 | By
European Pharmaceutical Review has brought together four individuals from different sides of the scientific palette to discuss current and future issues surrounding secondary screening and maximising its potential.
19 March 2008 | By
The process analytical technology guidelines have been a hotly debated topic within the pharmaceutical industry ever since they were made public in 2004. This also holds true at Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), Division of Janssen Pharmaceutical N.V. In recent years, the company has introduced PAT tools…
